The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
Open accessAbstract
BACKGROUND: Papillary renal-cell carcinoma, which accounts for 15 to 20% of renal-cell carcinomas, is a heterogeneous disease that consists of various types of renal cancer, including tumors with indolent, multifocal presentation and solitary tumors with an aggressive, highly lethal phenotype. Little is known about the genetic basis of sporadic papillary renal-cell carcinoma, and no effective forms of therapy for advanced disease exist. METHODS: We performed comprehensive molecular characterization of 161 primary papillary renal-cell carcinomas, using whole-exome sequencing, copy-number analysis, messenger RNA and microRNA sequencing, DNA-methylation analysis, and proteomic analysis. RESULTS: Type 1 and type 2 papillary renal-cell carcinomas were shown to be different types of renal cancer characterized by specific genetic alterations, with type 2 further classified into three individual subgroups on the basis of molecular differences associated with patient survival. Type 1 tumors were associated with MET alterations, whereas type 2 tumors were characterized by CDKN2A silencing, SETD2 mutations, TFE3 fusions, and increased expression of the NRF2-antioxidant response element (ARE) pathway. A CpG island methylator phenotype (CIMP) was observed in a distinct subgroup of type 2 papillary renal-cell carcinomas that was characterized by poor survival and mutation of the gene encoding fumarate hydratase (FH). CONCLUSIONS: Type 1 and type 2 papillary renal-cell carcinomas were shown to be clinically and biologically distinct. Alterations in the MET pathway were associated with type 1, and activation of the NRF2-ARE pathway was associated with type 2; CDKN2A loss and CIMP in type 2 conveyed a poor prognosis. Furthermore, type 2 papillary renal-cell carcinoma consisted of at least three subtypes based on molecular and phenotypic features. (Funded by the National Institutes of Health.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“another possible mechanism by which D-2-HG drives tumorigenesis is through the promotion of genetic instability, predisposing cells to oncogenic transformation103.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [103]
In the citing paper
“Genomic studies have established that somatic mutations in IDH1 and IDH2 are perhaps the first genetic events to occur during tumorigenesis in human glioma and AML, and appear to initiate pathogenesis by a common mechanism103,115-117.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [103]
In the citing paper
“The most commonly occurring cancers thought to arise from mutant IDH1/2 (mIDH1/2) include glioma, cartilaginous tumours, AML, angioimmunoblastic T cell lymphoma (AITL) and intrahepatic cholangiocarcinoma (ICC).”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [103]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Self-citationComprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177
Comprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485
Self-citationDiscovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
The Multiple Leiomyoma Consortium (2002) · Nature Genetics · doi:10.1038/ng849 · Cited by 1,635
Flagged first, then by citations
1 of the 42 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Delahunt B, 1997, Mod Pathol, 10, 537
- Schmidt LS, 1998, Cancer Res, 58, 1719
Cited by
Sorted by citations
Items 701–800 of 1,000
Wang, Y., Zheng, X., Huang, W., Lu, J., Hou, N., Qi, J., Ma, J., Xue, W., Zheng, J., & Zhai, W. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.83302 · Cited by 11
Alam, R., Rezaee, M. E., Pallauf, M., Elias, R. M., Yerrapragada, A., Enikeev, D. V., Fang, D., Shariat, S. F., Woldu, S. L., Ged, Y. M. A., et al. (2023) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2023.08.016 · Cited by 11
Wang, Y., Chen, X., Tang, N., Guo, M., & Ai, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25074134 · Cited by 11
The Role of the PAX Genes in Renal Cell Carcinoma
Li, L., Hossain, S. M., & Eccles, M. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126730 · Cited by 11
Li, X., Lin, D., Xiong, Y., Lin, W., Zhang, S., Huang, S., Zhou, J., & Dai, C. (2025) · European Radiology · doi:10.1007/s00330-025-11446-y · Cited by 11
Recent Developments in the Management of Renal Cell Cancer
Chen, Y., Panian, J. A., Rose, B. S., Bagrodia, A., & McKay, R. R. (2025) · JCO Oncology Practice · doi:10.1200/op-24-00875 · Cited by 11
Targeting the disrupted Hippo signaling to prevent neoplastic renal epithelial cell immune evasion
Lv, X., Liu, J., Ruan, J., Chen, P., He, C., Zhao, X., Huang, C., Chen, L., Wang, H., Hua, G., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57697-7 · Cited by 11
Asrani, K. V., Mendes, A. A. D. A., Woo, J., Abadchi, S. N., Vidotto, T., Imada, E. L., Skaist, A. M., Feng, K., Liu, H. B., Kasbe, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63885-2 · Cited by 11
Contrastive learning enhances fairness in pathology artificial intelligence systems
Lin, S.-Y., Tsai, P.-C., Su, F.-Y., Chen, C.-Y., Li, F., Zhao, J., Ho, Y. Y., Lee, M. T., Healey, E., Lin, P.-J., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102527 · Cited by 13
Bellut, J., Bertz, S., Nolte, E., Stöhr, C., Polifka, I., Lieb, V., Herrmann, E., Jung, R., Hartmann, A., Wullich, B., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-16144-4 · Cited by 11
Wang, Z., Jiang, M., Feng, N., & Li, C. (2018) · Biochimie · doi:10.1016/j.biochi.2018.07.005 · Cited by 11
Syed, J. S., Brito, J. M., Pooli, A. H., Boutros, P. C., & Shuch, B. M. (2020) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2019.12.003 · Cited by 11
Wang, X., Zhang, D., Zhang, C., & Sun, Y. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.02.94 · Cited by 11
Hirotsu, Y., Yokoyama, H., Amemiya, K., Hagimoto, T., Hosaka, K., Oyama, T., Mochizuki, H., & Omata, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01643 · Cited by 11
Mauro, I. D., Dadone‐Montaudié, B., Sibony, M., Ambrosetti, D., Molinié, V., Decaussin‐Petrucci, M., Bland, V., Arbaud, C., Cenciu, B., Arbib, F., et al. (2021) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22985 · Cited by 11
Self-citationAl‐Obaidy, K. I., Alruwaii, Z. I., Williamson, S. R., & Liang Cheng, C. (2022) · Histopathology · doi:10.1111/his.14641 · Cited by 11
Ortiz-Estévez, M., Samur, M., Towfic, F., Flynt, E., Stong, N., Wang, K., Wang, K., Vyas, P., Munshi, N. C., Avet‐Loiseau, H., et al. (2021) · BMC Medical Genomics · doi:10.1186/s12920-021-01140-5 · Cited by 11
Trevisani, F., Floris, M., Vago, R., Minnei, R., & Cinque, A. (2022) · Cells · doi:10.3390/cells11101658 · Cited by 11
Oncogenic Role of miR-217 During Clear Cell Renal Carcinoma Progression
Zamora-Fuentes, J. M., Lemus, E. H., & Enríquez, J. E. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.934711 · Cited by 11
Emerging target discovery and drug repurposing opportunities in chordoma
Freed, D. M., Sommer, J., & Punturi, N. B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1009193 · Cited by 11
Tabrizi, P. F., Peters, I., Schimansky, I. M., Dubrowinskaja, N., Reese, C., Tezval, H., Kuczyk, M. A., & Serth, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216476 · Cited by 11
Predictive and prognostic biomarkers in urological tumours
Cimadamore, A., Franzese, C., Loreto, C. D., Blanca, A., Antonio Lopez-beltran, B., Crestani, A., Giannarini, G., Tan, P. H., Carneiro, B. A., El‐Deiry, W. S., et al. (2023) · Pathology · doi:10.1016/j.pathol.2023.10.016 · Cited by 12
Karpathiou, G., Batistatou, A. K., Forest, F., Clémenson, A., & Péoc’h, M. (2016) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000124 · Cited by 11
Morshaeuser, L., May, M., Burger, M., Otto, W., Hutterer, G. C., Pichler, M., Klatte, T., Wild, P. J., Buser, L., & Brookman-May, S. D. (2017) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.11.011 · Cited by 11
Fay, A. P., McKay, R. R., Lin, X., Simantov, R., & Choueiri, T. K. (2018) · Journal of Global Oncology · doi:10.1200/jgo.17.00119 · Cited by 11
GCN2 is a potential prognostic biomarker for human papillary renal cell carcinoma
Ge, L., Chen, W., Cao, W., Liu, G., Zhang, Q., Zhuang, J., Zhang, M., Yang, J., Guo, S., Zhao, X., et al. (2018) · Cancer Biomarkers · doi:10.3233/cbm-170922 · Cited by 13
Pheochromocytoma/Paraganglioma: A Poster Child for Cancer Metabolism
Tevosian, S. G., & Ghayee, H. K. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01991 · Cited by 11
The genomic landscape of pediatric renal cell carcinomas
Beck, P., Selle, B., Madenach, L., Jones, D., Vokuhl, C., Gopisetty, A., Nabbi, A., Brecht, I. B., Ebinger, M., Wegert, J., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104167 · Cited by 10
Papillary Renal Cell Carcinoma: A Review of Prospective Clinical Trials
Maughan, B. L., & Sirohi, D. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01107-x · Cited by 10
Immune-Based and Novel Therapies in Variant Histology Renal Cell Carcinomas
Miller, J. W., Johnson, J. S., Guske, C. W., Mannam, G., Hatoum, F., Nassar, M., Potez, M., Fazili, A. N., Spiess, P. E., & Chahoud, J. (2025) · Cancers · doi:10.3390/cancers17020326 · Cited by 10
Simeth, J., Engelmann, S. U., Mayr, R., Kälble, S., Weber, F., Pichler, R., Dettmer, K., Oefner, P. J., Höring, M., Symeou, L., et al. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102513 · Cited by 11
Prendeville, S., Richard, P. O., Jewett, M. A. S., Kachura, J. R., Sweet, J., van der Kwast, T., Cheung, C. C., Finelli, A., & Evans, A. J. (2019) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2018-205655 · Cited by 10
Nunno, V. D., Massari, F., Mollica, V., Cimadamore, A., Santoni, M., Liang Cheng, C., Antonio Lopez-beltran, B., Scarpelli, M., & Montironi, R. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.06.06 · Cited by 10
Light, A., Ahmed, A., Prokar Dasgupta, A., & Elhage, O. (2020) · British Journal of Urology · doi:10.1111/bju.15084 · Cited by 10
Blajan, I., Miersch, H., Schmidt, D. H., Kristiansen, G., Perner, S., Ritter, M., Ellinger, J., & Klümper, N. (2020) · European Urology Focus · doi:10.1016/j.euf.2020.09.007 · Cited by 10
Renal neoplasia with papillary architecture involving the pelvicalyceal system
Gupta, S., Cheville, J. C., Galeano, B. K., Sukov, W. R., Herrera-Hernandez, L. P., Reed, K. A., Lohse, C. M., Thompson, R. H., Boorjian, S. A., Leibovich, B. C., et al. (2020) · Human Pathology · doi:10.1016/j.humpath.2020.10.013 · Cited by 10
Chen, W.-C., Zhou, J., Sheltzer, J. M., Kinney, J. B., & McCandlish, D. M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025782118 · Cited by 10
The epigenetic–metabolic interplay in gliomagenesis
Phasaludeen, B., Emerald, B. S., & Ansari, S. A. (2022) · Open Biology · doi:10.1098/rsob.210350 · Cited by 10
SEOM SOGUG clinical guideline for treatment of kidney cancer (2022)
Méndez, M. J., Quintela, M. L., Milagro, N. L., Pérez‐Valderrama, B., Suárez, C., Arija, J. Á. A., Fernández, I. P., Gallardo, E., Sorrosal, J. L., & del Alba, A. G. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03276-5 · Cited by 10
Non-Clear Cell Renal Cell Carcinoma: Current Management and Best Practice
Salgia, M. M., Adashek, J. J., Bergerot, P. G., & Pal, S. K. (2017) · Kidney Cancer · doi:10.3233/kca-170019 · Cited by 10
Management of Small Renal Masses
Chenam, A., & Lau, C. (2018) · Cancer treatment and research · doi:10.1007/978-3-319-93339-9_5 · Cited by 10
Lee, H. J., Lee, A. Y. M., Huang, H. H., & Lau, W. K. O. (2019) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2019.02.014 · Cited by 10
The Prognostic Value of DNA Methylation Markers in Renal Cell Cancer: A Systematic Review
Peters, I., Merseburger, A. S., Tezval, H., Lafos, M., Tabrizi, P. F., Mazdak, M., Wolters, M., Kuczyk, M. A., Serth, J., & von Klot, C. A. J. (2020) · Kidney Cancer · doi:10.3233/kca-190069 · Cited by 10
Zheng, B., Xie, F., Cheng, F., Wang, J., Yao, Z., He, W., & Niu, Z. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.760031 · Cited by 10
Prognostic value of CDCA3 in kidney renal papillary cell carcinoma
Li, H., Li, M., Yang, C., Guo, F., Deng, S., Li, L., Ma, T., Yan, J., Wu, H., & Li, X. (2021) · Aging · doi:10.18632/aging.203767 · Cited by 10
Katzendorn, O., Peters, I., Dubrowinskaja, N., Moog, J. M., Reese, C., Tezval, H., Tabrizi, P. F., Hennenlotter, J., Lafos, M., Kuczyk, M. A., et al. (2021) · Cancers · doi:10.3390/cancers14010039 · Cited by 10
Johnson, M., Nowlan, S., Şahin, G., Barnett, D. A., Joy, A. P., Touaibia, M., Čuperlović‐Culf, M., Avizonis, D. Z., & Turcotte, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.841054 · Cited by 10
Epigenomic Consequences of Coding and Noncoding Driver Mutations
Yao, X., Xing, M., Ooi, W. F., Tan, P. B. O., & Teh, B. T. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.09.002 · Cited by 10
Nagaya, N., Kanayama, M., Nagata, M., & Horie, S. (2018) · Internal Medicine · doi:10.2169/internalmedicine.0663-17 · Cited by 10
Papillary Renal Cell Carcinoma: A Family Portrait
Flippot, R., Compérat, É., Tannir, N. M., & Malouf, G. G. (2017) · European Urology · doi:10.1016/j.eururo.2017.06.004 · Cited by 10
SCINA: Semi-Supervised Analysis of Single Cells in silicoPreprint
Zhang, Z., Luo, M. S. D., Zhong, X., Choi, J. H., Ma, Y., Mahrt, E., Guo, W., Stawiski, E. W., Wang, S., Modrusan, Z. D., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/559872 · Cited by 11
The emerging role of NF2 alterations in new and established subtypes of renal cell carcinoma
Paintal, A., & Antic, T. (2022) · Human Pathology · doi:10.1016/j.humpath.2022.06.008 · Cited by 9
Renal mass biopsy — a practical and clinicopathologically relevant approach to diagnosis
Mansour, H., Tran‐Dang, M., Walkden, M., Boleti, E., Barod, R., Patki, P., Mumtaz, F., Tran, M. G. B., Bex, A., & Sheikh, S. E. (2024) · Nature Reviews Urology · doi:10.1038/s41585-024-00897-5 · Cited by 9
Noronha, K. J., Lucas, K. N., Paradkar, S., Edmonds, J., Friedman, S., Murray, M. A., Liu, S., Sajed, D. P., Sachs, C. R., Spurrier, J. M., et al. (2024) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-23-1003 · Cited by 9
Oki, R., Takemura, K. N., Urasaki, T., Fujiwara, R., Numao, N., Yonese, J., Miura, Y., & Yuasa, T. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2491647 · Cited by 9
The role of the MET/AXL pathway as a new target for multikinase inhibitors in renal cell carcinoma
Nunno, V. D., Cubelli, M., & Massari, F. (2017) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2017.1347481 · Cited by 9
Trilla‐Fuertes, L., Miranda, N. F., Castellano, D., López‐Vacas, R., Farfán, C. A., de Velasco, G., Villacampa, F., López‐Camacho, E., Prado-Vázquez, G., Zapater‐Moros, A., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229075 · Cited by 9
Erlmeier, F., Steffens, S., Stöhr, C., Herrmann, E., Polifka, I., Agaimy, A., Trojan, L., Ströbel, P., Becker, F. O., Wülfing, C., et al. (2020) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2020.07.002 · Cited by 9
Bioinformatics in urology — molecular characterization of pathophysiology and response to treatment
Gheinani, A. H., Kim, J., You, S., & Adam, R. M. (2023) · Nature Reviews Urology · doi:10.1038/s41585-023-00805-3 · Cited by 9
Integrative Analysis of Germline Rare Variants in Clear and Non–clear Cell Renal Cell Carcinoma
Han, S. H., Camp, S. Y., Chu, H., Collins, R. L., Gillani, R., Park, J., Bakouny, Z., Ricker, C. A., Reardon, B. M., Moore, N., et al. (2024) · European Urology Open Science · doi:10.1016/j.euros.2024.02.006 · Cited by 9
Kiyozawa, D., Iwasaki, T., Takamatsu, D., Kohashi, K., Miyamoto, T., Fukuchi, G., Eto, M., Yamashita, M., & Oda, Y. (2024) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-024-03840-6 · Cited by 9
Genetic validation of a TSC2 immunohistochemistry assay in TSC/mTOR-pathway altered renal tumors
Akbari, A., Villanueva, C. R., Hes, O., Williamson, S. R., Kandukuri, S. R., Sharma, S., Aditi, A., Pivovarčíková, K., Argani, P., Mohanty, S. K., et al. (2024) · Human Pathology · doi:10.1016/j.humpath.2024.105693 · Cited by 9
Insights into the role of NRF2 in cancer provided by cancer genomics
Pölönen, P., & Levonen, A. (2016) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2016.09.002 · Cited by 9
Percutaneous biopsy in large, locally advanced or metastatic renal tumors
Wittmann, T. A., & Abel, E. J. (2016) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2016.10.003 · Cited by 9
The genomics of renal cell carcinoma and its role in renal mass biopsy
Salami, S. S., George, A. K., & Udager, A. M. (2018) · Current Opinion in Urology · doi:10.1097/mou.0000000000000516 · Cited by 9
Koudijs, K. K. M., van Scheltinga, A. G. T. T., Böhringer, S., Schimmel, K. J. M., & Guchelaar, H. (2019) · Scientific Reports · doi:10.1038/s41598-019-39891-y · Cited by 9
Circulating tumor DNA analysis of metastatic renal cell carcinoma
Zhang, J., Liu, Y., Xu, B., Li, F., Wang, Y., Li, M., Du, R., Zhou, Y., Salgia, M. M., Yang, L., et al. (2020) · Molecular and Clinical Oncology · doi:10.3892/mco.2020.2178 · Cited by 9
Three-dimensional coculture provides an improved in vitro model for papillary renal cell carcinoma
Rosette, K. A., Lander, S. M., VanOpstall, C., & Looyenga, B. D. (2021) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00141.2021 · Cited by 9
Gargiuli, C., Sepe, P., Tessari, A., Sheetz, T. J., Colecchia, M., de Braud, F., Procopio, G., Sensi, M., Verzoni, E., & Dugo, M. (2021) · Cancers · doi:10.3390/cancers13122903 · Cited by 9
Kidney cancer: from genes to therapy
Webster, B. R., Rompré‐Brodeur, A., Daneshvar, M., Pahwa, R., & Srinivasan, R. (2021) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2021.100773 · Cited by 9
Expression of nectin-4 in papillary renal cell carcinoma
Zschäbitz, S., Mikuteit, M., Stöhr, C., Herrmann, E., Polifka, I., Agaimy, A., Trojan, L., Ströbel, P., Becker, F. O., Wülfing, C., et al. (2022) · Discover Oncology · doi:10.1007/s12672-022-00558-2 · Cited by 9
WHO-Klassifikation von 2016 und erste S3-Leitlinie zum Nierenzellkarzinom
Moch, H. (2016) · Der Pathologe · doi:10.1007/s00292-016-0144-1 · Cited by 9
Kouba, E., Eble, J. N., Simper, N. B., Grignon, D. J., Wang, M., Zhang, S., Wang, L., Martignoni, G., Williamson, S. R., Brunelli, M., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.133 · Cited by 9
Ancillary studies in fine needle aspiration of the kidney
Renshaw, A. A., & Gould, E. W. (2018) · Cancer Cytopathology · doi:10.1002/cncy.22029 · Cited by 9
Practical Molecular Testing in a Clinical Genitourinary Service
Magers, M. J., & Liang Cheng, C. (2019) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2019-0134-ra · Cited by 9
Guan, Y., Gong, Z., Xiao, T., & Li, Z. (2018) · Europe PMC (PubMed Central) · Cited by 9
Chen, L., & Wang, D. (2021) · World Journal of Surgical Oncology · doi:10.1186/s12957-021-02129-1 · Cited by 9
The first competing risk survival nomogram in patients with papillary renal cell carcinoma
Su, X., Hou, N., Yang, L., Li, P.-X., Yang, X., Hou, G., Gao, X., Ma, S., Guo, F., Zhang, R., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-91217-z · Cited by 9
Metabolic reprogramming and elevation of glutathione in chromophobe renal cell carcinomasPreprint
Xiao, Y., Clima, R., Busch, J. F., Rabien, A., Kilic, E., Villegas, S. L., Türkmen, S., Timmermann, B., Attimonelli, M., Jung, K., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/649046 · Cited by 9
Grimm, S. L., Karki, M., Blum, K. A., Bertocchio, J., He, R., Tripathi, D. N., Zacharias, N. M., Lebenthal, J. M., Sheth, R. A., Rao, P., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3324 · Cited by 8
Owoicho, A. M., Ogenyi, D. O., Zhilenkova, A. V., Essogmo, F. E., Uchendu, I. K., Tchawe, Y. S. N., Pascal, A. M., Nikitina, N. M., Onoja, S. O., Pavliv, M. P., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136161 · Cited by 8
Zhang, H., Liu, Y., Liu, W., Lin, A., Fang, Y., Qu, L., Zhang, X., Luo, P., Wang, L., & Jiang, A. (2025) · Biomarker Research · doi:10.1186/s40364-025-00811-0 · Cited by 8
Pfefer, T., Bessenyei, A. H., & O'Neill, L. A. J. (2026) · Immunology Letters · doi:10.1016/j.imlet.2026.107153 · Cited by 8
Patient-Derived Xenograft Tumor Models: Overview and Relevance to IR
Sheth, R. A., Perkons, N. R., Dondossola, E., Subudhi, S. K., Gade, T. P. F., & Tam, A. L. (2018) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2018.01.782 · Cited by 8
Huang, M., Ye, X., Imakura, A., & Sakurai, T. (2022) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2022.104049 · Cited by 8
Urman, D. S., Deshler, L., Weise, N., Shabaik, A. S., Derweesh, I., Bagrodia, A., Rose, B. S., Herchenhorn, D., & McKay, R. R. (2023) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2023.09.004 · Cited by 8
DCLRE1B/Apollo germline mutations associated with renal cell carcinoma impair telomere protection
Bories, C., Lejour, T., Adolphe, F., Kermasson, L., Couvé, S., Tanguy, L., Luszczewska, G., Watzky, M., Poillerat, V., Garnier, P., et al. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167107 · Cited by 9
Nakazawa, S., Pecci, F., Ricciuti, B., Gottlieb, F. H., Facchinetti, F., Harada, G., Chen, M. F., Repetto, M., Giacomini, F., Jiang, J., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.03.045 · Cited by 8
Kwon, J. W., Wang, P., Wanjari, P., Wuori, D., Paik, J., Pytel, P., Fitzpatrick, C. A., Tjota, M. Y., & Antic, T. (2025) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000002442 · Cited by 8
Cancer Genetics and Therapeutic Opportunities in Urologic Practice
Adashek, J. J., Leonard, A., Roszik, J., Menta, A. K., Genovese, G., Subbiah, V., & Msaouel, P. (2020) · Cancers · doi:10.3390/cancers12030710 · Cited by 8
Pan cancer patterns of allelic imbalance from chromosomal alterations in 33 tumor types
Sivakumar, S., Lucas, F. A. S., Jakubek, Y. A., Özcan, Z., Fowler, J., & Scheet, P. A. (2021) · Genetics · doi:10.1093/genetics/iyaa021 · Cited by 8
Duan, M., Zhang, L., Wang, Y., Fan, Y., Liu, S., Yu, Q., Huang, L., & Zhou, F. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104571 · Cited by 8
Different Fumarate Hydratase Gene Variants Are Associated With Distinct Cancer Phenotypes
Kamihara, J., Horton, C., Tian, Y., Zhou, J., Richardson, M. E., LaDuca, H., & Rana, H. Q. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00263 · Cited by 8
Wu, P., Xiang, T., Wang, J., Lv, R., Ma, S., Yuan, L., Wu, G., & Che, X. (2021) · BMC Medical Genomics · doi:10.1186/s12920-021-01092-w · Cited by 8
McClain, K. M., Sampson, J. N., Petrick, J. L., Mazzilli, K. M., Gerszten, R. E., Clish, C. B., Purdue, M. P., Lipworth, L. P., & Moore, S. C. (2022) · Metabolites · doi:10.3390/metabo12121189 · Cited by 8
Kamińska, K., Czarnecka, A. M., Khan, M. I., Fendler, W. M., Klemba, A., Krasowski, P., Bartnik, E., & Szczylik, C. A. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4234 · Cited by 8
Singh, J. A., Ohe, C., & Smith, S. C. (2018) · Pathology International · doi:10.1111/pin.12667 · Cited by 8
Lessons learned from the developmental origins of childhood renal cancer
Chong, W. C., & Cain, J. E. (2019) · The Anatomical Record · doi:10.1002/ar.24315 · Cited by 8
Is percutaneous image-guided renal tumour ablation ready for prime time?
Cazzato, R. L., Garnon, J., Marini, P. D., Auloge, P., Koch, G., Dalili, D., Buy, X., Palussière, J., Rao, P. P., Tricard, T., et al. (2020) · British Journal of Radiology · doi:10.1259/bjr.20200284 · Cited by 8
Merino, M. J., Ricketts, C. J., Moreno, V., Yang, Y., Fan, T. W. ‐., Lane, A. N., Meltzer, P. S., Vocke, C. D., Crooks, D. R., & Linehan, W. M. (2020) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001611 · Cited by 8
Metadata
- Authors
- The Cancer Genome Atlas Research Network
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- The Cancer Genome Atlas Research Network
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-01-14
- Volume
- 374
- Issue
- 2
- Pages
- 135-145
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4775252
- OpenAlex
- W2111867681
- Cited by
- 1,336
- References
- 42
- Citations by year
- 2026: 60 · 2025: 100 · 2024: 95 · 2023: 130 · 2022: 135 · 2021: 159 · 2020: 153 · 2019: 151 · 2018: 128 · 2017: 126 · 2016: 96
- FWCI
- 92.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (UL1TR000005)
- National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG003273)
- National Cancer Institute (K24CA172355, U24CA143882, U24CA143843, U24CA143840, U24CA143858, U24CA144025, U24CA143866, U24CA199461, U24CA143883, U24CA143845, U24CA180951, U24CA143867, R01CA169172, U24CA143848, U24CA143799, U24CA143835, P30CA008748, P30CA015083, P30CA016672, P30CA016056, P30CA016086)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- papillary renal cell carcinoma, type 2 papillary renal cell carcinoma, MET alterations, SETD2 mutation, TFE3 fusion, Nrf2/ARE pathway, CpG island methylator phenotype, tumor subtypes, prognosis, molecular heterogeneity
- MeSH terms
- Carcinoma, Papillary, Humans, Kidney Neoplasms, Mutation, Phenotype, RNA, Messenger, RNA, Neoplasm, Signal Transduction, Sequence Analysis, RNA, CpG Islands, DNA Methylation, Proto-Oncogene Proteins c-met, MicroRNAs, NF-E2-Related Factor 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
